FDA Approves Orzeyful for Narcolepsy Type 1
Orzeyful is the first drug to target the underlying loss of orexin signaling to address the full range of narcolepsy type 1.
Orzeyful is the first drug to target the underlying loss of orexin signaling to address the full range of narcolepsy type 1.
The Society of Thoracic Surgeons (STS) appointed Justine Varieur Turco as its CEO and executive director, effective August 31, 2026.
For patients in the pediatric ICU, pulse oximetry and waveform capnography are valuable tools to monitor the effectiveness of respiratory support and to inform treatment decisions.
Magnolia Diagnostics and its owners allegedly billed Medicare for unnecessary respiratory panels performed on seniors during the pandemic, according to the US Justice Dept.
A proof-of-concept study showed an experimental monoclonal antibody targeting ARDS inflammation increased ventilator-free days and reduced organ failure.
Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii and the FungiFlex Mold Plus Panel testing assays.
New research suggests acoustic speech features can identify respiratory exacerbations from the first day of onset.